Merck & Co., Inc. - Product Pipeline Review

Transcription

1 Report Information More information from: Merck & Co., Inc. - Product Pipeline Review Report / Search Code: WGR Publish Date: 22 March, 2016 Price 1-user PDF : $ Site PDF : $ Enterprise PDF : $ Description: Merck & Co., Inc. - Product Pipeline Review Summary Global Markets Direct s, Merck & Co., Inc. - Product Pipeline Review , provides an overview of the Merck & Co., Inc. s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Merck & Co., Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Merck & Co., Inc. - The report provides overview of Merck & Co., Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages - The report assesses Merck & Co., Inc. s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Merck & Co., Inc. s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate Merck & Co., Inc. s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Merck & Co., Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Merck & Co., Inc. s pipeline depth and focus of pipeline therapeutics

2 - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Contents: Table of Contents Table of Contents 2 List of Tables 7 List of Figures 7 Merck & Co., Inc. Snapshot 8 Merck & Co., Inc. Overview 8 Key Information 8 Key Facts 8 Merck & Co., Inc. - Research and Development Overview 9 Key Therapeutic Areas 9 Merck & Co., Inc. - Pipeline Review 21 Pipeline Products by Stage of Development 21 Pipeline Products - Monotherapy 22 Pipeline Products - Combination Treatment Modalities 23 Pipeline Products - Partnered Products 24 Pipeline Products - Out-Licensed Products 28 Merck & Co., Inc. - Pipeline Products Glance 31 Merck & Co., Inc. - Late Stage Pipeline Products 31 Merck & Co., Inc. - Clinical Stage Pipeline Products 34 Merck & Co., Inc. - Early Stage Pipeline Products 38 Merck & Co., Inc. - Drug Profiles 42 (elbasvir + grazoprevir) 42 asenapine maleate 44 bezlotoxumab 45 desloratadine 46 diquafosol tetrasodium 48 fosaprepitant dimeglumine 50 insulin glargine 51 narlaprevir 53 pembrolizumab 54 (actoxumab + bezlotoxumab) 64 (atorvastatin calcium + ezetimibe) 65 (ceftolozane sulfate + tazobactam sodium) 66 (cilastatin sodium + imipenem + relebactam) 68 (doravirine + lamivudine + tenofovir disoproxil fumarate) 69 actoxumab 70 anacetrapib 71 corifollitropin alfa 73 doravirine 75 fidaxomicin 77 letermovir 81 odanacatib 82 omarigliptin 84 posaconazole 86 solithromycin 87 standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen extract 90 tedizolid phosphate 93 V V verubecestat 101 vibegron 102 vorinostat 103 (grazoprevir + MK MK-8408) 107 BQ dalotuzumab 110 elbasvir + grazoprevir + MK grazoprevir 114 lomerizine 116 lonafarnib 117 mirtazapine ODT 119 MK MK MK selumetinib sulfate 124

3 MK MK MK samatasvir 130 temozolomide 132 V MK vorapaxar sulfate 137 CB insulin human 140 MK MK MK MK MK MK MK MK MK MK MK MK MK MK MK MK Monoclonal Antibody for Autoimmune Diseases 159 NB rituximab biosimilar 161 Small Molecule 1 for Human Cytomegalovirus Infection 162 Small Molecule 2 for Human Cytomegalovirus Infection 163 V V BNC CB chikungunya (viral like particles) vaccine 169 DORA Drug to Inhibit 11Beta-HSD1 for Hypertension 171 ETP GP GRA J8-CRM mdx MK MK MK MK MK MK MK Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia 185 Monoclonal Antibody for Cancer 186 MRK MRK MRLB Proteins for Cancer, Autoimmune and Inflammatory diseases 190 PTC PTC PTC PyP respiratory syncytial virus vaccine 195 SCH SCH Small Molecule 3 for Human Cytomegalovirus Infection 198 Small Molecule to Agonize Glucocorticoid Receptor for Respiratory Disorders 199 Small Molecule to Antagonize Glucagon Receptor for Type 2 Diabetes 200 Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Staphylococcus aureus Infection 201

4 Small Molecule to Inhibit ROMK for Hypertension and Heart Failure 202 Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis 203 Small Molecules for Undisclosed Indications 204 Small Molecules to Agonize GPR119 for Metabolic Disorders 205 Small Molecules to Agonize M1 for Alzheimer s Disease 206 Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease 208 Small Molecules to Block Cav2.2 Channel for Chronic Pain 209 Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases 210 Small Molecules to Inhibit DGAT1 211 Small Molecules to Inhibit DHFR for Septicaemia 212 Small Molecules to Inhibit PRMT5 for Haemoglobinopathies and Solid Tumours 213 Small Molecules to Inhibit Prolyl Hydroxylase for Anemia 214 Small Molecules to Inhibit Renin for Hypertension 215 THPP TROX XEN XL Drug to Target GPCR for Undisclosed Indication 220 Kibdelomycin A 221 MK Monoclonal Antibodies for Undisclosed Indication 223 Monoclonal Antibody for Neurology 224 SCH Small Molecules to Antagonize Adenosine 2A receptor for Undisclosed Indication 226 Small Molecules to Inhibit Inositol Phosphorylceramide for Fungal Infections 227 Small Molecules to Inhibit IRAK4 for Inflammatory Diseases 228 Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation 229 Small Molecules to Inhibit NS5A for Hepatitis C 230 Small Molecules to Inhibit PPI for Undisclosed Indication 231 Undisclosed Biosimilars 233 Merck & Co., Inc. - Pipeline Analysis 234 Merck & Co., Inc. - Pipeline Products by Target 234 Merck & Co., Inc. - Pipeline Products by Route of Administration 240 Merck & Co., Inc. - Pipeline Products by Molecule Type 242 Merck & Co., Inc. - Pipeline Products by Mechanism of Action 243 Merck & Co., Inc. - Recent Pipeline Updates 248 Merck & Co., Inc. - Dormant Projects 323 Merck & Co., Inc. - Discontinued Pipeline Products 331 Discontinued Pipeline Product Profiles 333 Merck & Co., Inc. - Company Statement 343 Merck & Co., Inc. - Locations And Subsidiaries 345 Head Office 345 Other Locations & Subsidiaries 345 Appendix 376 Methodology 376 Coverage 376 Secondary Research 376 Primary Research 376 Expert Panel Validation 376 Contact Us 376 Disclaimer 377 List of Tables Merck & Co., Inc., Key Information 19 Merck & Co., Inc., Key Facts 19 Merck & Co., Inc. - Pipeline by Indication, Merck & Co., Inc. - Pipeline by Stage of Development, Merck & Co., Inc. - Monotherapy Products in Pipeline, Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, Merck & Co., Inc. - Partnered Products in Pipeline, Merck & Co., Inc. - Partnered Products/ Combination Treatment Modalities, Merck & Co., Inc. - Out-Licensed Products in Pipeline, Merck & Co., Inc. - Out-Licensed Products/ Combination Treatment Modalities, Merck & Co., Inc. - Pre-Registration, Merck & Co., Inc. - Phase III, Merck & Co., Inc. - Phase II, Merck & Co., Inc. - Phase I, Merck & Co., Inc. - Preclinical, Merck & Co., Inc. - Discovery,

5 Merck & Co., Inc. - Pipeline by Target, Merck & Co., Inc. - Pipeline by Route of Administration, Merck & Co., Inc. - Pipeline by Molecule Type, Merck & Co., Inc. - Pipeline Products by Mechanism of Action, Merck & Co., Inc. - Recent Pipeline Updates, Merck & Co., Inc. - Dormant Developmental Projects, Merck & Co., Inc. - Discontinued Pipeline Products, Merck & Co., Inc., Subsidiaries 356 List of Figures Merck & Co., Inc. - Pipeline by Top 10 Indication, Merck & Co., Inc. - Pipeline by Stage of Development, Merck & Co., Inc. - Monotherapy Products in Pipeline, Merck & Co., Inc. - Combination Treatment Modalities in Pipeline, Merck & Co., Inc. - Partnered Products in Pipeline, Merck & Co., Inc. - Out-Licensed Products in Pipeline, Merck & Co., Inc. - Pipeline by Top 10 Target, Merck & Co., Inc. - Pipeline by Top 10 Route of Administration, Merck & Co., Inc. - Pipeline by Top 10 Molecule Type, Merck & Co., Inc. - Pipeline Products by Top 10 Mechanism of Action, wiseguyreports.com / Phone (US) (UK)